European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

EUbOPEN: Enabling and Unlocking biology in the OPEN

Descrizione del progetto

DE EN ES FR IT PL

Scoperta di farmaci su larga scala

C’è un bisogno pressante di nuovi farmaci che abbiano selettivamente come bersaglio e che inibiscano proteine umane quali i vettori di soluti e le ligasi ubiquitina E3. Il progetto EUbOPEN, finanziato dall’UE, mira a generare la più grande libreria disponibile gratuitamente di composti che coprano un terzo del genoma utilizzabile come bersaglio farmacologico. I partner caratterizzeranno la selettività, la potenza e l’attività cellulare degli inibitori delle proteine prestando particolare attenzione alla malattia infiammatoria intestinale, al cancro e alla neurodegenerazione. Le tecnologie generate dovrebbero ridurre notevolmente i processi di identificazione da composto capostipite a composto guida (hit to lead) e promuovere il processo di scoperta di farmaci in generale. EUbOPEN si assocerà con altri grandi progetti per coordinare gli sforzi legati alla scoperta di farmaci a livello globale.

Obiettivo

The EUbOPEN partnership of excellence will aim to generate the largest freely available set of high-quality chemical inhibitors for human proteins. These compounds will include chemical probes for solute carriers (SLCs), E3-ubiquitin ligases (E3s) and other proteins, and a chemogenomic library (CGL) of 3000-5000 compounds covering one third of the druggable genome. All compounds in the sets will be comprehensively characterised defining their selectivity, potency and cellular activity. The compounds will be annotated with a series of established and novel biochemical and cell-based assays, including many derived from primary patient cells. Diseases of particular focus will be inflammatory bowel disease, cancer and neurodegeneration.
EUbOPEN partners have proven track records leading large international open science projects, developing unencumbered key reagents, and exploring new target areas. A strong commitment to open data and open science will accelerate the dissemination of knowledge and reagents as well as mitigate ethical issues that might arise by working with patient-derived cells.
EUbOPEN will partner extensively with other large projects (e.g. ReSOLUTE, Illuminating the Druggable Genome) to minimize duplication of effort and to maximize global coordination. EUbOPEN will provide via the EFPIA partners the public access to industry’s deep medicinal chemistry skills.
Sustainability of the project’s resources will be ensured through already established partnerships with chemical vendors and cheminformatics/database providers, which will ensure the long-term availability of the new chemical tool sets, all associated profiling data and established protocols.
The EUbOPEN project will form the foundation for future efforts to generate chemical modulators for the entire druggable genome and will develop new technologies significantly shortening hit and lead identification processes.

Campo scientifico

Parole chiave

Programma(i)

Argomento(i)

Invito a presentare proposte

H2020-JTI-IMI2-2019-17-two-stage

Vedi altri progetti per questo bando

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN
Contribution nette de l'UE
€ 7 171 503,00
Indirizzo
THEODOR W ADORNO PLATZ 1
60323 Frankfurt Am Main
Germania

Mostra sulla mappa
Regione
Hessen Darmstadt Frankfurt am Main, Kreisfreie Stadt
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 9 905 000,00

Partecipanti (22)

Condividi questa pagina

Scarica

Ultimo aggiornamento: 9 Luglio 2024

Il mio booklet

Permalink: https://cordis.europa.eu/project/id/875510/it

European Union, 2024